Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;42(2):299-307.
doi: 10.1055/s-0041-1722964. Epub 2021 Feb 6.

Determinants and Management of the Post-Pulmonary Embolism Syndrome

Affiliations
Review

Determinants and Management of the Post-Pulmonary Embolism Syndrome

Gudula J A M Boon et al. Semin Respir Crit Care Med. 2021 Apr.

Abstract

Acute pulmonary embolism (PE) is not only a serious and potentially life-threatening disease in the acute phase, in recent years it has become evident that it may also have a major impact on a patient's daily life in the long run. Persistent dyspnea and impaired functional status are common, occurring in up to 50% of PE survivors, and have been termed the post-PE syndrome (PPES). Chronic thromboembolic pulmonary hypertension is the most feared cause of post-PE dyspnea. When pulmonary hypertension is ruled out, cardiopulmonary exercise testing can play a central role in investigating the potential causes of persistent symptoms, including chronic thromboembolic pulmonary disease or other cardiopulmonary conditions. Alternatively, it is important to realize that post-PE cardiac impairment or post-PE functional limitations, including deconditioning, are present in a large proportion of patients. Health-related quality of life is strongly influenced by PPES, which emphasizes the importance of persistent limitations after an episode of acute PE. In this review, physiological determinants and the diagnostic management of persistent dyspnea after acute PE are elucidated.

PubMed Disclaimer

Conflict of interest statement

F.A.K. and G.J.A.M.B. were supported by the Dutch Heart Foundation (2017T064). F.A.K. reports grants from Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Daiichi Sankyo, MSD, Actelion, Netherlands Thrombosis Foundation, and Dutch Heart Foundation. M.V.H. reports grants from ZonMW Dutch Healthcare Fund and Aspen, and grants and personal fees from Boehringer Ingelheim, Pfizer-BMS, Bayer Health Care, and Daiichi-Sankyo..